Drug Conjugates with Polyglycerols

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses drug delivery systems where pharmaceutically or diagnostically active compounds are covalently attached to dendritic polyglycerol-based polymers, optionally with a polyethylene glycol (PEG) shell. These conjugates use cleavable linkers that release the active compound in response to specific triggers (such as enzymes, pH, or hydrolysis) at the site of disease, enhancing the localization and efficacy of treatment drugs (including cytostatic agents like doxorubicin). The approach improves drug targeting, decreases side effects, and allows the co-delivery of multiple agents.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted cancer chemotherapy with reduced systemic toxicity.
• Drug delivery for autoimmune or inflammatory diseases requiring localization within affected tissues.
• Delivery of antibiotics or antiviral agents to infection sites, minimizing off-target effects.
• Combination therapies where multiple drugs are delivered simultaneously on a single carrier for synergistic effects.
• Diagnostic imaging or therapy by delivering contrast agents or radioactive markers to specific tissues.
• Personalized medicine applications through customizable carriers for patient-specific drug combinations.

BenefitsContent extracted from patent full text and abstract with AI.

• Improved targeted delivery of drugs to disease sites, maximizing efficacy and minimizing adverse effects.
• Reduction in drug toxicity due to decreased exposure to healthy tissues.
• Enhanced pharmacokinetics and prolonged circulation time enabled by the polymer and PEG shell.
• Ability to load multiple active agents (same or different) on a single carrier, supporting combination therapies.
• Release of active drugs can be precisely controlled via environmentally sensitive cleavable linkers responding to disease-specific triggers (e.g., tumor-associated enzymes or pH).
• Improved solubility and biocompatibility of poorly soluble drugs via polymer conjugation.
• Versatility for use with a wide range of pharmaceutical or diagnostic compounds.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a drug polymer conjugate comprising a pharmaceutically active compound and a dendritic polyglycerol, as well as to a drug polymer conjugate comprising a pharmaceutically and/or diagnostically active compound bound to a dendritic polyglycerol core having a polyethylene glycol shell.